Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315766 | 1.00 | MAPT (0.47) | MAPTCACNA1BAPBA1APPTDP1 | |
| Hydrochloric Acid SCHEMBL670412 | 0.80 | MAPT (0.46) | MAPTCACNA1BAPBA1APPTSHR | |
| Hydrochloric Acid SCHEMBL670413 | 0.80 | MAPT (0.46) | MAPTCACNA1BAPBA1APPTSHR | |
| SCHEMBL663908 | 0.79 | HCAR2 (0.52) | MAPTCYP3A4ALDH1A1HCAR2ATM | |
| SCHEMBL6050194 | 0.79 | MAPT (0.52) | MAPTCACNA1BAPBA1APPTDP1 | |
| SCHEMBL663907 | 0.79 | HCAR2 (0.52) | MAPTCYP3A4ALDH1A1HCAR2ATM | |
| SCHEMBL4799130 | 0.79 | MAPT (0.52) | MAPTCACNA1BAPBA1APPTDP1 | |
| SCHEMBL36139 | 0.77 | MAPT (0.69) | MAPTCACNA1BAPBA1APPTDP1 | |
| SCHEMBL6885967 | 0.77 | MAPT (0.69) | MAPTCACNA1BAPBA1APPTDP1 | |
| SCHEMBL36375 | 0.77 | MAPT (0.69) | MAPTCACNA1BAPBA1APPTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758471-B2 | Process for the preparation of 4-dimethylaminocrotonic acid | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20170107172-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-04-20 | — | — | US | disclosed |
| EP-3148977-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | Sun Pharmaceutical Industries Ltd (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186065-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107172-A1 | PROCESS FOR THE PREPARATION OF 4-DIMETHYLAMINOCROTONIC ACID | EGFR, MET, ABL1 | MAPT 3324/4885CACNA1B 3599/4885APBA1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.